Biomind Labs Inc. ("Biomind Labs"), a leading biotech company specializing in cutting-edge pharmaceuticals for neurological disorders, has released a comprehensive corporate update, highlighting its remarkable progress in research and development, intellectual property expansion, and clinical trial advancements.

In a statement, Alejandro Antalich, CEO of Biomind Labs, emphasized the significance of the upcoming fourth quarter of 2023. He revealed that pivotal data from the company's Phase IIa clinical trial, featuring a double-blind, randomized, placebo-controlled, repeated single-dose study, is on the horizon. This data is expected to be a game-changer in Alzheimer's disease treatment, a debilitating condition responsible for 60-70% of dementia cases.

Key advancements include:

BMND01: N,N-dimethyltryptamine ("DMT") Extraction and Purification: Biomind Labs has perfected an extraction process, ensuring high yields and purity, adhering to Good Laboratory Practices ("GLP"). This achievement marks a significant step in pharmaceutical development.

BMND01: DMT Inhaled Formulation: The efficient administration of a DMT inhaled formulation via a vaporizer device ensures precise and consistent dosing, enabling rapid relief for patients with neurological symptoms.

BMND01: DMT Intramuscular Formulation ("IM"): Biomind Labs has optimized an isotonic DMT fumarate IM formulation, offering an accessible alternative for patients who cannot tolerate oral medications.

BMND07: 5-methoxy-DMT ("5-MeO-DMT") Free Base Organic Synthesis: The successful synthesis of 5-MeO-DMT freebase as an Active Pharmaceutical Ingredient ("API") with exceptionally high purity represents a major milestone.

BMND02: 5-MeO-DMT Nasal Formulation: A nasal formulation prototype has been designed, showing positive drug mucosal membrane permeation through in vitro assays.

BMND08: 5-MeO-DMT Sublingual Formulation: This sublingual formulation offers rapid onset, high bioavailability, precise dosing, and improved patient compliance. It demonstrates remarkable safety and tolerability in clinical trials.

Micro/Nanoparticles Pharmaceutical Formulations: Innovative nano pharmaceutical formulations of DMT and 5-MeO-DMT for oral administration have been developed.

Mescaline Preclinical Cell-based Assays: Mescaline demonstrates promising anti-inflammatory properties, outperforming dexamethasone in reducing the production of IL-6.

Mescaline Sustainable Production: Biomind Labs has successfully developed artificial bacteria strains for scalable, Good Manufacturing Practices ("GMP") compliant mescaline production.

Intellectual Property Portfolio: The company has filed over 20 patent applications worldwide, reinforcing its commitment to protecting groundbreaking biotechnology inventions.

Biomind Labs continues its mission to provide modern, affordable treatments for psychiatric and neurological conditions, leveraging innovative pharmaceutical formulations and nanotech delivery systems.

Read release: https://www.businesswire.com/news/home/20230927568679/en/